Navigation Links
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
Date:1/6/2014

160;

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  In early 2014, the Company plans to initiate a phase 2, clinical proof of concept study in acute limb ischemia that will evaluate whether MST-188 improves the effectiveness of existing thrombolytic agents.  The Company also is evaluating development options in heart failure.  More information can be found on the Company's web site at www.masttherapeutics.com.  (Twitter: @MastThera)

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding MST-188's prospects in heart failure, the potential market in that indication, and the Company's development plans for MST-188 in heart failure and in acute limb ischemia, including the timing of initiation of any clinical studies.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Acsis Inc., the market leader for supply chain ... John DiPalo , Acsis, Chief Strategy Officer, has ... Executive 2015 Provider Pro to Know. The award ... help prepare their companies, and customers, supply chains for ... list of Provider Pros to Know is featured in ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, ... pre-clinical studies that,provide evidence for chemotherapy ... (ABRAXANE(R) for Injectable,Suspension (paclitaxel protein-bound particles ... drugs like,bevacizumab (Avastin(R)) at the 98th ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... results from two pre-clinical studies that,support the ... rich in,cysteine) expression in cancer and Abraxis' ... Association for Cancer Research (AACR) Annual Meeting ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5
(Date:3/1/2015)... (PRWEB) March 01, 2015 “ The Barrel ... monthly Tech Report, which takes a look at the latest ... Tropeano, the host of NewsWatch and a technology expert, conducted ... spiral adds flavor to drinks. , According to Home Distillation ... the best spirits. Well, there’s a pretty cool product that’ll ...
(Date:2/28/2015)... 2015 The MCA Youth Empowerment Conference ... one platform and gears towards the goal for a ... of group talks in smaller groups will be held ... Personal Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women ... Malaysian youths. , Young adults aged between ...
(Date:2/28/2015)... In a recent episode of SCI TV ... Athlete Development Services and Consultancy talks with Joshua ... development and player engagement during and after their careers. ... face and how off-field activities are a critical component ... in athlete development issues while in graduate school coaching ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 28, 2015 Mew and Company, a ... they now provide business consulting services in addition to ... tax planning and succession planning. Company finances are a ... professionals. On top of this, complex Canadian tax laws ... accounting. As a result, Mew and Company works to ...
Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... According to an inquest heard, a patient was given a lethal ... than 100 hours in a week.// ,Dr Helen Pike, ... her. The patient, Tony Wright, 58 suffered a massive cardiac arrest ... in the hospital’s ICU. ,Once his wife heard about ...
... for a new study has shown that even few pounds overweight ... compared// to those who maintain the optimum weight. ... was conducted involving 500,000 people, which took into consideration their lifestyle ... , ,The study revealed that obese people carried ...
... costs as well as indirect costs for employers, ... Occupational and Environmental// Medicine, official publication of the ... ,Led by Dr. Gene Colice of ... a large insurance database to analyze costs associated ...
... a spurt in cases of diarrhea, nausea, and vomiting, which ... outbreak. ,A common infection at this time ... to have taken a virulent form. It would do good ... infection. It is important to wash hands well after the ...
... has found a way to reduce brain swelling, the most ... doctoral student Renée Turner in the Discipline of Pathology at ... brain seems to mimic a similar process in the skin, ... these are yet to be developed. ,“This potentially ...
... American and South African scientists working at the epicenter ... how the human immunodeficiency virus// (HIV) “exhausts” killer T ... found that HIV can simply “turn off” fully functional ... cells. In test tube studies, however, the scientists showed ...
Cached Medicine News:Health News:Sheer exhaustion makes a junior doc’ kill a patient! 2Health News:Sheer exhaustion makes a junior doc’ kill a patient! 3Health News:Insurance Data Show High Costs of Persistent Asthma 2Health News:How HIV "Exhausts" Killer T Cells 2Health News:How HIV "Exhausts" Killer T Cells 3Health News:How HIV "Exhausts" Killer T Cells 4
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With reinforced ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With reinforced ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
Medicine Products: